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hematologic recovery was observed in most patients, with values of
ANC 	500 and platelet 	20,000 being reached at 13 and 16 days,
respectively. Cardiac toxicity was monitored by echocardiogram.
All patients demonstrated a normal left ventricular ejection frac-
tion (LVEF) prior to receiving the conditioning regimen. There
were no deaths attributable to heart failure. A signiﬁcant decline in
LVEF developed in only one patient who was over age 60 with
underlying diabetes and hypertension. Ninety-four percent of pa-
tients survived the ﬁrst 100 days following transplant. To date, 7
patients are alive and in remission at 2 to 7 years since disease
onset, with no patients lost to follow-up. The 3-year failure-free
and overall survival are 44% and 55%, respectively. We conclude
that high dose mitoxantrone and melphalan is an effective and
easily administered conditioning regimen with a low risk of signif-
icant cardiac toxicity despite prior treatment with anthracycline
based chemotherapy, and thus is a safe regimen for APBSCT in
adults with AML.
265
COMPARISON OF FIXED DOSE (6 MG) PEGFILGRASTIM AND DAILY
FILGRASTIM TO ACCELERATE HEMOPOIETIC RECOVERY AFTER AU-
TOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
Marcacci, G.1, Petti, M.C.2, Ferrara, F.3, Scarpato, N.4, Storti, S.5,
D’Arena, G.1, Palombi, F.2, Palmieri, S.3, Andretta, C.4, Pinto, A.1 1.
Hematology Oncology and Bone Marrow Transplantation Unit, Na-
tional Cancer Institute, Fondazione “Pascale” IRCCS, Naples, Italy; 2.
Hematology Unit, National Cancer Institute, “Regina Elena” IRCCS,
Rome, Italy; 3. Hematology and BMT Unit, AORN “Cardarelli”,
Naples, Italy; 4. Hemapheresis Unit, AOU “Federico II”, Naples, Italy;
5. Hematology Oncology Unit, Catholic University, Campobasso, Italy.
High dose therapy plus Autologous Stem Cell Transplantation
(ASCT) is a milestone treatment program for most hematologic
malignancies. ASCO guidelines recommend the use of granulocyte
colony stimulating factors (G-CSF) in the post-infusion phase, to
shorten the period of severe neutropenia and reduce the related
risk of life-threatening infections. Thus, daily subcutaneous injec-
tions of G-CSF (ﬁlgrastim/lenograstim) at 5 g/kg dose until
ANC 	 500/l are routinely administered from day 1 following
ASCT, in order to accelerate hematopoietic recovery and to avoid
neutropenic complications. Pegﬁlgrastim, a novel long-acting re-
combinant G-CSF, has been shown to have similar efﬁcacy when
compared to G-CSF for chemotherapy-induced neutropenia, but
little is known about its use in the ASCT setting. We used a 6 mg
ﬁxed dose Pegﬁlgrastim on day 4 following ASCT in 47 patients
(23 male/24 female; median age 56 years; range 22–70 years) with
multiple myeloma (26 pts) and relapsed or refractory Hodgkin’s
and non- Hodgkin’s lymphoma (21 pts). Patients received periph-
eral CD34 stem cells (median number 4.4  106/kg; range 1.8–
1.8) harvested after mobilizing chemotherapy (cytoxan, vinorel-
bine/cytoxan, R-IEV, IGEV, R-ICE) and G-CSF. Standard
conditioning regimens (HD-Melphalan or BEAM) were used. En-
graftment results were compared to those from a historical control
group of 182 patients (median age 56 years; range 16–74 years)
who had received HD-Melphalan or BEAM and ASCT (median
CD34 cells 7.6  106/kg; range 1.8–14.6) supported by G-CSF
(5 g/kg/day from day 1 until ANC 	 500/l). Median number
of days to ANC 	 500/l were comparable between the Pegﬁl-
grastim (10, range 8–15) and G-CSF (11, range 7–22) groups, as
well as the median number of days to PLT 	 20,000/l (Pegﬁl-
grastim  12, range 9–20 vs G-CSF  12, range 7–29). Overall
infectious rates, including FUO and documented infections, were
of 48% and 39% for Pegﬁlgrastim and G-CSF groups, respectively
(P  NS). Median number of days on iv antibiotics were 0 (range
0–18) and 6 (range 0–13) for the Pegﬁlgrastim and G-CSF groups,
respectively. No signiﬁcant differences in the incidence of bone
pain, intensity of transfusion support, and length of hospital stay
were documented between the two groups. These data indicate
that a ﬁxed 6 mg single-dose of Pegﬁlgrastim is safe and effective
to accelerate engraftment after ASCT. No signiﬁcant differences
with G-CSF were apparent as to engraftment times and overall
infectious complications.
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Eight adult patients with hematological malignancies were enrolled
in a phase I IVBU dose-escalation trial in autologous BMT condi-
tioning. All patients received four daily doses of IVBU followed by 2
days of cyclophosphamide (CP) with amifostine cytoprotection.
There were 4 planned cohorts of patients with an increasing targeted
IVBU AUC of 20% in each subsequent cohort. The targeted average
daily AUC range for IVBU in cohort 1 was 4400–5280 uMolmin/
dose (mean 4800), the AUC range commonly achieved by single daily
doses of 3.2 mg/kg/day. PK data from 6 time points over 5 hours was
obtained from an IVBU test dose of 0.4 mg/kg administered to
patients 7 to 21 days prior to conditioning. Test dose data was used to
achieve the targeted IVBU AUC for conditioning doses 1 and 2.
IVBU PK data was also collected around conditioning doses 1 and 3
at 7 points over 20 hours. If the targeted daily AUC range was not
achieved based on the IVBU PK data for dose 1, IVBU doses were
adjusted to correct the AUC during days 3 and 4 IVBU was measured
in plasma samples using a validated gas chromatography method.
Acetaminophen and metronidazole were held during all IVBU ad-
ministration. Fungal prophylaxis was the same during IVBU test and
conditioning doses. Patients received phenytoin for seizure prophy-
laxis. All PK data followed expected pharmacokinetic behavior. In
cohort no. 1, test dose PK data resulted in achieving the targeted
AUC for 3 of 5 (60%), but in none of the 3 patients in cohort no. #2
based on ﬁrst IVBU conditioning dose PK results. The test dose PK
data resulted in a lower than targeted AUC in 5 patients. Of these 5
patients, 4 achieved the targeted 4-day AUC after dose adjustments.
Hepatic veno-occlusive disease was diagnosed in 2 patients in cohort
no. 2 after IVBU doses were increased to obtain the targeted mean
4-day AUC. The study was closed. Utilizing PK data based on a small
pretransplant IVBU test dose with limited blood sampling of up to 5
hours did not accurately predict conditioning AUCs, especially when
higher targeted AUCs were desired. PK data from ﬁrst dose IVBU
conditioning dose was more predictive of later IVBU conditioning
AUCs. This suggests that conditions during the test dose as proposed
in this study did not accurately reﬂect those of conditioning and/or
that a higher test dose with more comprehensive blood sampling
might be more predictive in estimating IVBU dose when single daily
busulfan is administered with targeting strategy (Table1).












1 4400–5280 3558 8590 6074
2 4400–5280 4864 4853 4858
3 4400–5280 5152 6232 5692
4 4400–5280 4771 4870 4820
5 4400–5280 4223 5358 4790
6 5281–6340 4034 6858 5446
7 5281–6340 4905 6586 5745
8 5281–6340 4051 6207 5129
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A major advance in the treatment of high-risk patients with solid
tumors has been to intensify therapy. We hypothesize that the use
of tandem high dose chemotherapy followed by stem cell rescue
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